Variance Decomposition Accesses a Clinically Supported Discovery Space Systematically Missed by Mean-Based Transcriptomic Prioritization
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Abstract Background Computational prioritization of therapeutic antigen candidates relies predominantly on mean-level differential expression (DEG) analysis. Whether this approach systematically excludes a clinically relevant tier of the transcriptome has not been formally tested. Methods We compared genome-wide variance decomposition (TANK) and mean-based ranking across 32 TCGA cancer types (60,656 genes), defining TANK-only, DEG-only, and shared gene sets. Clinical pipeline enrichment was assessed by Fisher's exact test against a curated database of approved and active therapeutic programs. Results TANK nominated 5,068 genes invisible to mean-based ranking (TANK-only), while mean-based methods exclusively nominated 2,009 genes (DEG-only). TANK-only genes were significantly enriched for active or approved clinical programs compared to DEG-only genes (9/5,068 [0.18%] vs. 0/2,009 [0.00%]; Fisher's exact p = 0.049), although the limited number of events warrants cautious interpretation. DEG-only genes exhibited substantially higher DepMap functional dependency than TANK-only genes (mean 0.348 vs. 0.098; p < 10–160), reflecting enrichment of core translational machinery rather than therapeutically tractable targets. Three independent prospective convergences were identified: CLDN6/BNT211 (Phase 1/2), SLC34A2/TUB-040 (Phase 1/2, NCT06303505), and MAGEA4/Tecelra (FDA-approved August 2024) — in each case with variance-based nomination preceding literature consultation. Conclusions Variance decomposition accesses a clinically supported tier of the cancer transcriptome distinct from and complementary to mean-based prioritization. These results establish variance decomposition as a quantitatively justified and empirically supported complement to differential expression analysis in computational oncology.
Fields of Study & Subjects
Gene expression and cancer classification
Bioinformatics and Genomic Networks
Computational Drug Discovery Methods
Publication details
- Journal / source
- Research Square
- Publication date
- 30 March 2026
- Language
- EN
- Document type
- Preprint